2013
Search results
Anne E. Wojcicki (/ w uː ˈ tʃ ɪ t s k i / woo-CHITS-kee; born July 28, 1973) is an American entrepreneur who co-founded and is CEO of the personal genomics company 23andMe. She founded the company in 2006 with Linda Avey and Paul Cusenza.
Jun 1, 2023 · Anne Wojcicki is the cofounder and CEO of 23andMe, a pioneering direct-to-consumer genetics testing firm based in South San Francisco, California. In June 2021, 23andMe went public in a...
May 20, 2021 · Anne Wojcicki, CEO of 23andMe, spent a decade in healthcare and biotechnology before launching the DNA testing and analysis company in 2006. Her goal was twofold: to help individuals learn more...
May 9, 2024 · Anne Wojcicki (born July 28, 1973, San Mateo county, California) is an American entrepreneur and cofounder and chief executive officer of the personal genetics company 23andMe. Wojcicki received a B.S. degree (1996) in biology from Yale University.
Apr 25, 2023 · Genetics have the potential to transform how we predict, prevent, and treat almost all human disease, writes 23andMe CEO Anne Wojcicki.
Apr 10, 2020 · The chief executive of one of the world’s leading — and most contentious — consumer genetic testing companies is reluctant to drag her seven-month-old daughter through the driving...
Linda Avey, Paul Cusenza and Anne Wojcicki founded 23andMe in 2006 to offer genetic testing and interpretation to individuals. Investment documents from 2007 also suggest that 23andMe hoped to develop a database to pursue research efforts.
Dec 7, 2021 · Anne Wojcicki, Chief Executive Officer of 23andMe, photographed for Forbes by Aaron Kotowski in June 2019. Aaron Kotowski/The Forbes Collection. The cofounder and CEO of 23andMe spoke to...
Anne Wojcicki. CEO and Co-Founder. Anne co-founded 23andMe in 2006, three years after the first human genome was sequenced. Her goal was audacious: to help people access, understand, and benefit from the human genome and fundamentally change healthcare in the process.
Jun 17, 2021 · Anne Wojcicki, the cofounder and CEO of 23andMe, owns 99.4 million shares of the merged company; with shares trading on the Nasdaq under the ticker “ME” at $13.40 as of 3:00pm EDT...
